{
    "clinical_study": {
        "@rank": "100741", 
        "arm_group": {
            "arm_group_label": "Mirodenafil"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and effectiveness of mirodenafil in\n      participants with erectile dysfunction."
        }, 
        "brief_title": "A Study to Evaluate the Safety and Effectiveness of Mirodenafil in Korean Patients With Erectile Dysfunction", 
        "completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "condition": "Erectile Dysfunction", 
        "condition_browse": {
            "mesh_term": "Erectile Dysfunction"
        }, 
        "detailed_description": {
            "textblock": "This is a non randomized (the study medication is not assigned by chance), open-label (all\n      participants and study staff know the identity of the treatment), multi-center, prospective\n      (looking forward using observations collected  following participant enrollment), and\n      non-comparative study in which  participants with erectile dysfunction will be observed to\n      evaluate the safety and effectiveness of mirodenafil for 12 weeks. Safety evaluations will\n      include assessment of adverse events, and record of concomitant medications. The study will\n      be conducted in Korea."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants  diagnosed with erectile dysfunction\n\n          -  Participants prescribed mirodenafil on demand\n\n        Exclusion Criteria:\n\n        - Participants who have administered mirodenafil for other than an approved indication"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Participants diagnosed with erectile dysfunction and prescribed mirodenafil on demand."
            }
        }, 
        "enrollment": {
            "#text": "379", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802359", 
            "org_study_id": "CR100836", 
            "secondary_id": [
                "MIRODENEDY4002", 
                "MIR-KOR-PMS"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Mirodenafil", 
            "description": "This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.", 
            "intervention_name": "No intervention", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Mirodenafil"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Erectile dysfunction", 
            "Mirodenafil", 
            "Bravonto"
        ], 
        "lastchanged_date": "May 27, 2013", 
        "number_of_groups": "1", 
        "official_title": "Post-Marketing Surveillance of Bravonto in Korea", 
        "overall_official": {
            "affiliation": "Janssen Korea, Ltd., Korea", 
            "last_name": "Janssen Korea, Ltd., Korea Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802359"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The International Index of Erectile Function is used for the assessment of erectile dysfunction, with scores ranging from 0 to 30. Evaluation of points are as follows: 1-10 = severe erectile dysfunction, 11-16 = moderate dysfunction, 17-21 = mild to moderate dysfunction, 22-25 = mild dysfunction, 26-30 = no dysfunction. Lower scores indicate worsening.", 
                "measure": "International Index of Erectile Function", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Week 0), Week 4, Week 8, and Week 12"
            }, 
            {
                "description": "The Sexual Encounter Profile is assessed after each sexual attempt consisting of a series of yes/no questions regarding specific aspects of each encounter. Question 1 asks, \"Were you able to insert your penis into your partner's vagina?\" and question 2 asks, \"Did your erection last long enough for you to complete intercourse with ejaculation?\".", 
                "measure": "Sexual Encounter Profile", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Week 0), Week 4, Week 8, and Week 12"
            }, 
            {
                "description": "The Global Assessment Questionnaire is a self-administered questionnaire (Yes/No) that allows men to rate improvement in erectile function. Question 1 asks \"Has the treatment you have been taking over the past 4 weeks improved your erections?\" and if the answer is yes, question 2 then asks \"Has the treatment improved your ability to engage in sexual activity\"", 
                "measure": "Global assessment Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Week 0), Week 4, Week 8, and Week 12"
            }, 
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "source": "Janssen Korea, Ltd., Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Korea, Ltd., Korea", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013", 
        "why_stopped": "This prodect will be transferred to another company."
    }
}